Clinical significance of hypodysfibrinogenemia γ 326 Cys -> Tyr?

Thromb Haemost 2005; 94(05): 1108-1109
DOI: 10.1160/TH05-05-1108

Letters to the Editor

Schattauer GmbH

Authors

Georg Aue

¹Hematology Branch, National Institute of Heart, Lung, and Blood
McDonald K. Horne III

²Department of Laboratory Medicine, W.G. Magnuson Clinical Center, National Institutes of Health, Bethesda, MD, USA

References
1 Dear A, Brennan SO, George PM. Familial hypodysfibrinogenaemia associated with second occurrence of γ 326 Cys–>Tyr mutation. Thromb Haemost 2005; 93: 612-3.
2 Meyer M, Franke K, Richter W. et al. New molecular defects in the gamma subdomain of fibrinogen D-domain in four cases of (hypo)dysfibrinogenemia: fibrinogen variants Hannover VI, Homburg VII, Stuttgart and Suhl. Thromb Haemost 2003; 89: 637-46.
3 Haverkate F, Samama M. Familial dysfibrinogenemia and thrombophilia. Report of a study of the SSC subcommittee on fibrinogen. Thromb Haemost 1995; 73: 151-61.
4 Dolan G, Greaves M, Cooper P, Preston FE. Thrombovascular disease and familial plasminogen deficiency: a report of three kindreds. Br J Haematol 1988; 70: 417-21.
5 de Bosch NB, Mosesson MW, Ruiz-Saez A. et al. Inhibition of thrombin generation in plasma by fibrin formation (antithrombin I). Thromb Haemost 2002; 88: 253-8.
6 Lind SE, Callas PW, Golden EA. et al. Plasma levels of factors II, VII, X and their relationship to the international normalized ratio during chronic warfarin therapy. Blood Coagul Fibrinol 1997; 8: 48-53.